Coral Laboratories Ltd is an **ISO 9001: 2008** certified pharmaceutical manufacturer and exporter based in India. The company specializes in **Pharmaceutical Formulations** and is currently undergoing a strategic transformation to become a vertically integrated healthcare provider across human, veterinary, and aqua-health segments. --- ### **Core Manufacturing Infrastructure & Strategic Relocation** The company maintains a robust manufacturing footprint designed to meet international quality standards. Recent infrastructure developments indicate a focus on scaling production to meet rising export demand. * **Dehradun, Uttarakhand (Pharma City, Selaqui):** This is a primary growth hub. In **March 2026**, the company successfully commissioned an expansion of its **General Pharmaceuticals Formulation (Ointment)** unit, bringing total capacity to **360,000 kgs**. * **Daman (Bhenslore, Dunetha):** A key manufacturing site supporting the company’s formulation output. * **Corporate Realignment:** In **November 2023**, the company shifted its registered office from **Vadodara, Gujarat**, to **Mumbai, Maharashtra**. This move was designed to centralize operations and improve coordination with the senior leadership team. --- ### **Financial Performance & Growth Trajectory** Coral Laboratories has demonstrated aggressive top-line and bottom-line growth, driven largely by its success in international markets. | Metric | FY 2024-25 (Rs. in Lacs) | FY 2023-24 (Rs. in Lacs) | FY 2022-23 (Rs. in Lacs) | | :--- | :---: | :---: | :---: | | **Total Revenue** | **12,411.39** | **9,029.28** | **8,501.35** | | **Profit After Tax (PAT)** | **2,415.56** | **1,578.90** | **644.54** | | **Export Revenue** | **9,474.85** | **6,200.57** | *Not Specified* | | **Dividend Per Share** | **₹1.50 (15%)** | **₹2.00 (20%)** | **N/A** | **Key Financial Highlights:** * **Revenue Growth:** The company achieved a **37.4%** year-on-year revenue increase in FY25. * **Profitability:** PAT surged by **~145%** between FY23 and FY24, maintaining strong momentum into FY25. * **Capital Structure:** The **Authorised Share Capital** stands at **₹10 Crore**, with a **Paid-up Equity Share Capital** of **₹3,57,26,000** (as of March 31, 2024). * **Liquidity Management:** The company maintains an **overdraft facility exceeding ₹5 crore**, secured against Fixed Deposits, to manage working capital requirements. --- ### **Strategic Pivot: Diversification into Life Sciences** In **September 2025**, the Board approved a significant expansion of the **Memorandum of Association (MOA)**. This marks a transition from a pure-play formulation firm to a diversified life sciences entity. **New Product Segments & Capabilities:** * **Upstream Integration:** Moving into the production of **basic drugs, intermediates, and medicinal chemicals**. * **Biotechnology & Specialized Therapeutics:** Manufacturing of **vaccines, enzymes, steroids, hormones, biologicals, and immunological preparations**. * **Animal & Aqua Health:** Entry into **veterinary medicines, aqua-culture treatments**, and specialized **herbal animal products**. * **Nutritional Science:** Processing of **yeasts, toxin-binders, feed additives, premixes, and granules**. * **Human Healthcare Portfolio:** Continued focus on **antibiotics, contraceptives, tonics, and vitamin-based preparations** across various delivery systems including **sprays and droppers**. --- ### **Export-Led Business Model** The company’s valuation strategy is heavily weighted toward international trade. * **Export Dominance:** Exports currently contribute approximately **76%** of total revenue. * **Global Trade Mandate:** The company is authorized to engage in the **import, export, and distribution** of pharmaceutical residues, by-products, and accessories globally. * **Compliance:** Financials are strictly prepared under **Indian Accounting Standards (Ind AS)** to ensure transparency for global stakeholders. --- ### **Risk Management & Internal Controls** Coral Laboratories employs a formal **Risk Management Framework** to mitigate volatility in the global pharmaceutical landscape. **Financial Risk Mitigation:** * **Credit Risk:** Managed by dealing with high-credit-rated banks and setting customer-specific risk limits. **Trade Receivables** stood at **₹33.64 crore** as of September 2025. * **Foreign Exchange Risk:** Given the high export volume, the company utilizes **foreign exchange derivatives** to hedge against currency fluctuations. * **Liquidity Risk:** Managed via **rolling cash flow forecasts** to ensure all obligations are met under both normal and stressed conditions. **Governance & Oversight:** * **Internal Audit:** Conducted by **M/s. S. K. Doshi & Associates** to appraise business risks and internal controls. * **Statutory Auditors:** **M/s. S C Mehra & Associates LLP** (Appointed for a 5-year term through 2030). * **Secretarial Auditors:** **M/s. SARK & Associates LLP** (Appointed for a 5-year term from May 2025). --- ### **Asset Quality & Solvency Profile** The company maintains a healthy balance sheet with no material uncertainty regarding its status as a **Going Concern**. | Asset Category | Sep 2025 (₹ Crore) | March 2024 (₹ Crore) | | :--- | :---: | :---: | | **Gross Trade Receivables** | **33.64** | **28.19** | | **Loans and Advances** | **0.55** | **0.55** | **Operational Stability:** * The company reports **cordial industrial relations** with no labor disruptions. * No **convertible securities, stock options, or warrants** have been issued, preventing equity dilution in the recent reporting period. * There are no significant adverse orders from **Regulators, Courts, or Tribunals** impacting the company's operational viability.